Payment overview · 2025
General Payments
$798.57
29 reported records · 13 companies
Healthcare provider profile · identity verified
Stephen Brown Henderson, MD
Allopathic & Osteopathic Physicians|Family Medicine · GUNTERSVILLE, AL · NPI 1366523110
Verified facts
What the public records show
CMS Open Payments records show Stephen Brown Henderson, MD received $798.57 in general payments during 2025 across 29 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $308.64 | 38.6% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $220.40 | 27.6% | 10 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $46.48 | 5.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44.30 | 5.5% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $30.45 | 3.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.49 | 2.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.77 | 2.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.27 | 2.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.70 | 2.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.01 | 2.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.34 | 2.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.77 | 1.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $13.95 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $791.77 | 28 |
| Education | $6.80 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $220.40 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $158.76 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $135.57 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $46.48 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $30.45 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.77 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 112 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 758 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 466 | 130 |
| Omeprazole | Omeprazole | 427 | 101 |
| Gabapentin | Gabapentin | 388 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 351 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 333 | 71 |
| Lisinopril | Lisinopril | 302 | 78 |
| Alprazolam | Alprazolam | 285 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 237 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 48 |
| Losartan Potassium | Losartan Potassium | 211 | 58 |
| Sertraline Hcl | Sertraline Hcl | 198 | 28 |
| Metformin Hcl | Metformin Hcl | 177 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 49 |
| Simvastatin | Simvastatin | 161 | 42 |
| Eliquis | Apixaban | 156 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 38 |
| Clonazepam | Clonazepam | 144 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 144 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 140 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 42 |
| Tramadol Hcl | Tramadol Hcl | 138 | 32 |
| Montelukast Sodium | Montelukast Sodium | 131 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 129 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 124 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 38 |
| Trazodone Hcl | Trazodone Hcl | 120 | 32 |
| Furosemide | Furosemide | 116 | 31 |
| Diazepam | Diazepam | 112 | 13 |
| Jardiance | Empagliflozin | 112 | 23 |
| Carvedilol | Carvedilol | 103 | 26 |
| Ibandronate Sodium | Ibandronate Sodium | 99 | 34 |
| Potassium Chloride | Potassium Chloride | 99 | 28 |
| Famotidine | Famotidine | 97 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 28 |
| Prednisone | Prednisone | 85 | 37 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 83 | 20 |
| Metformin Hcl Er | Metformin Hcl | 81 | 29 |
| Mounjaro | Tirzepatide | 80 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 74 | 53 |
| Lorazepam | Lorazepam | 74 | 14 |
| Meloxicam | Meloxicam | 74 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 74 | 16 |
| Ozempic | Semaglutide | 72 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 13 |
| Spironolactone | Spironolactone | 66 | 11 |
| Bupropion Xl | Bupropion Hcl | 65 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 13 |
| Ibuprofen | Ibuprofen | 62 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 59 | 13 |
| Terazosin Hcl | Terazosin Hcl | 59 | 13 |
| Meclizine Hcl | Meclizine Hcl | 54 | 18 |
| Mirtazapine | Mirtazapine | 54 | 22 |
| Amoxicillin | Amoxicillin | 51 | 39 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 16 |
| Allopurinol | Allopurinol | 49 | 14 |
| Azithromycin | Azithromycin | 49 | 42 |
| Glimepiride | Glimepiride | 49 | 13 |
| Lovastatin | Lovastatin | 49 | 13 |
| Fluconazole | Fluconazole | 48 | 27 |
| Dutasteride | Dutasteride | 47 | 16 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Finasteride | Finasteride | 45 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 43 | 11 |
| Donepezil Hcl | Donepezil Hcl | 42 | 13 |
| Gemtesa | Vibegron | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 37 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Linzess | Linaclotide | 36 | 12 |
| Temazepam | Temazepam | 36 | suppressed |
| Naproxen | Naproxen | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 28 |
| Cilostazol | Cilostazol | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 27 |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 13 |
| Armour Thyroid | Thyroid,pork | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Belbuca | Buprenorphine Hcl | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | 11 |
| Torsemide | Torsemide | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 19 |
| Mupirocin | Mupirocin | 22 | 17 |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Celecoxib | Celecoxib | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 14 |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Buprenorphine | Buprenorphine | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 13 |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 11 |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $798.57 · 29 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CREON, Cologuard Collection Kit, FANAPT, FARXIGA, INSPIRE, JARDIANCE, JOURNAVX, Kerendia, LINZESS, NUZYRA, Ohtuvayre, REXULTI, Sunosi, WATCHMAN Access System | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error